You are here

  • Home
  • Archive
  • Volume 12, Issue 5
  • Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Article info

Article menu
Immune cell therapies and immune cell engineering
Original research
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers

Authors

  • Tessa Gargett University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Nga T H Truong University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Bryan Gardam University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Wenbo Yu University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Lisa M Ebert University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Amy Johnson Flinders University, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Erica C F Yeo University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, Australia PubMed articlesGoogle scholar articles
  • Nicole L Wittwer University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Gonzalo Tapia Rico Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Jesikah Logan Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Purany Sivaloganathan Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Maria Collis Surgical Pathology, SA Pathology, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Andrew Ruszkiewicz Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaSurgical Pathology, SA Pathology, Adelaide, South Australia, AustraliaSchool of Pharmacy and Medical Science, University of South Australia, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles
  • Michael P Brown University of South Australia, Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, Rundle Mall, South Australia, AustraliaAdelaide Medical School, The University of Adelaide, Adelaide, South Australia, AustraliaCancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia PubMed articlesGoogle scholar articles

Citation

Gargett T, Truong NTH, Gardam B, et al
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers
Journal for ImmunoTherapy of Cancer 2024;12:e008659. doi: 10.1136/jitc-2023-008659
Online issue publication 
May 15, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.